Objectives: Smear-negative pulmonary TB (PTB) is difficult to diagnose. Current diagnosis and treatment monitoring methods have inherent limitations. Droplet digital PCR (ddPCR) is a new technique with high sensitivity. This study presents a novel ddPCR for rapid and sensitive identification of Mycobacterium tuberculosis (MTB).
Methods: MTB DNA was detected in respiratory specimens from suspected PTB cases using ddPCR assay, which was directed at two different locations within IS6110. We, for the first time, evaluated the clinical diagnostic ability of this ddPCR for paucibacillary smear-negative PTB.
Results: A total of 605 PTB suspects were recruited, including 263 patients with confirmed PTB (84.03% from smear-negative PTB) and 342 without PTB. The sensitivity and specificity of IS6110 ddPCR were 61.22% (95% confidence interval (CI) 55.00-67.10%) and 95.03% (95% CI 92.20-97.10%) for total PTB and 57.92% (95% CI 51.10-64.50%) and 94.57% (95% CI 91.20-96.90%) for smear-negative PTB. ddPCR assay outperformed Xpert MTB/RIF (53.08% vs 28.46%, P = 0.020) in smear-negative PTB detection. Furthermore, effective anti-TB treatment was linked to significantly lower IS6110 copies detected by ddPCR.
Conclusion: Herein, we developed and validated a highly sensitive and robust ddPCR assay for MTB quantification in respiratory specimens, which improves diagnosis and therapeutic effect evaluation of smear-negative PTB.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ijid.2022.07.041 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Diagnostic value of SAT-TB in smear-negative pulmonary tuberculosis: A diagnostic accuracy study.
Medicine (Baltimore)
December 2024
Infection Department, Suining Central Hospital, Suining, Sichuan, China.
This study aimed to evaluate the diagnostic value of rapid simultaneous RNA amplification and testing for tuberculosis (SAT-TB) in smear-negative pulmonary tuberculosis (PTB). We performed a multicenter prospective analysis of 206 patients with smear-negative suspected PTB between December 2018 and March 2022. We collected sputum or bronchoalveolar lavage fluid (BALF) for simultaneous SAT-TB and Xpert Mycobacterium tuberculosis/rifampin (MTB/RIF) assays.
View Article and Find Full Text PDFStudy on the early diagnostic value of nanopore sequencing in alveolar lavage fluid smear-negative pulmonary tuberculosis.
Braz J Microbiol
December 2024
Department of Infectious Diseases, Xiangya Medical College, Zhuzhou Central Hospital (Zhuzhou Hospital, Central South University), Zhuzhou, Hunan, 412007, China.
The objective of this study was to investigate the early diagnostic value of nanopore sequencing in alveolar lavage smear-negative pulmonary tuberculosis (PTB). A prospective study was conducted on patients hospitalized at Zhuzhou Central Hospital from October 2021 to June 2022 and suspected to have PTB. Alveolar lavage fluid specimens were collected from these patients and simultaneously subjected to centrifugal bacterial collection smear method in a sandwich cup, bifidobacteria solid culture (referred to as culture), Mycobacterium tuberculosis-DNA (TB-DNA), and nanopore sequencing for detection of Mycobacterium tuberculosis.
View Article and Find Full Text PDFMicrobiological aspects and clinical impact of lower lung field tuberculosis: An observational cohort study in Peru.
Int J Infect Dis
January 2025
Department of Global Health and Social Medicine, Harvard Medical School, Boston, MA, USA; Division of Global Health Equity, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA. Electronic address:
Article Synopsis
- Approximately 40% of global tuberculosis cases go undiagnosed, with lower lung field TB (LLF TB) frequently misidentified as other lung issues, causing treatment delays.
- An observational study in Lima, Peru, found that among 1316 pulmonary TB patients, 6% had LLF TB, which tended to be smear-negative, indicating a less typical presentation of the disease.
- LLF TB patients showed less improvement in their respiratory health after 2 months of treatment, yet they had better final treatment outcomes compared to those with non-LLF TB, highlighting the need for optimized care for this specific group.
Enhanced diagnosis of pulmonary tuberculosis through nucleotide MALDI-TOF MS analysis of BALF: a retrospective clinical study.
Sci Rep
August 2024
Department of Clinical Laboratory, Chongqing Public Health Medical Center, Southwest University Public Health Hospital, Chongqing, China.
Article Synopsis
- The study evaluated the effectiveness of nucleotide MALDI-TOF MS in diagnosing pulmonary tuberculosis (PTB) using bronchoalveolar lavage fluid (BALF) from 960 suspected patients.
- It compared the sensitivity and negative predictive value (NPV) of MALDI-TOF MS with other diagnostic methods, finding it significantly more effective than smear microscopy, MGIT culture, and Xpert MTB/RIF.
- The results suggest that nucleotide MALDI-TOF MS could be a valuable tool for the early diagnosis of PTB, particularly in cases where other methods show negative results.
Nanopore sequencing for smear-negative pulmonary tuberculosis-a multicentre prospective study in China.
Ann Clin Microbiol Antimicrob
June 2024
Tuberculosis Department, Beijing Chest Hospital, Capital Medical University, Beijing, 101149, PR China.
Purpose: In this prospective study, the diagnosis accuracy of nanopore sequencing-based Mycobacterium tuberculosis (MTB) detection was determined through examining bronchoalveolar lavage fluid (BALF) samples from pulmonary tuberculosis (PTB) -suspected patients. Compared the diagnostic performance of nanopore sequencing, mycobacterial growth indicator tube (MGIT) culture and Xpert MTB/rifampin resistance (MTB/RIF) assays.
Methods: Specimens collected from suspected PTB cases across China from September 2021 to April 2022 were tested then assay diagnostic accuracy rates were compared.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!